A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

ClinicalTrials.gov ID: NCT06792695

Public ClinicalTrials.gov record NCT06792695. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Study identification

NCT ID: NCT06792695
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Metastatic Colorectal Cancer

Interventions

Volrustomig Drug
FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) Drug
Bevacizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 11, 2025
Primary completion: Jun 29, 2027
Completion: Sep 28, 2028
Last update posted: Aug 17, 2026

2025 – 2028

United States locations

U.S. sites: 14
U.S. states: 14
U.S. cities: 14

Facility	City	State	ZIP	Site status
Research Site	Scottsdale	Arizona	85259	Recruiting
Research Site	Los Angeles	California	90089	Recruiting
Research Site	Washington D.C.	District of Columbia	20007	Recruiting
Research Site	Chicago	Illinois	60637	Not yet recruiting
Research Site	Baltimore	Maryland	21224	Recruiting
Research Site	Boston	Massachusetts	02114	Completed
Research Site	Rochester	Minnesota	55905	Recruiting
Research Site	Trenton	New Jersey	08690	Recruiting
Research Site	Rochester	New York	14618	Recruiting
Research Site	Cleveland	Ohio	44106	Withdrawn
Research Site	Portland	Oregon	97239	Not yet recruiting
Research Site	Philadelphia	Pennsylvania	19104	Withdrawn
Research Site	Nashville	Tennessee	37232	Not yet recruiting
Research Site	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06792695, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 17, 2026 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06792695 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →